认识和联系Profil的专家

简介

Leona在肥胖症、糖尿病和新陈代谢领域拥有深厚的科学及医学专业知识。她在学术界和业界都拥有强大的研究背景，尤其是在分子内分泌学和能量代谢的基础科学方面拥有独到的专业知识。

此外，她在营养保健品的生物活性食品化合物开发过程中具有丰富的经验。Plum-Mörschel博士也是一位活跃的学术讲师，她还是糖尿病和内分泌相关专业科学学会的会员。肥胖与前驱糖尿病部门结合了糖尿病与心脏代谢研究的独特经验，营养科学的专业内容以及Profil代谢病房的可用性。该部门可以帮助设计和开展针对人体肥胖的智能且全面的临床试验。这些试验既可以作为主要的研究重点，也可以作为改善血糖控制、代谢疾病风险或其他重大合并症的手段。

发表物

以下是Leona的近期发表物:

• Flint A, Andersen G, Hockings P, Johansson L, Morsing A, Palle MS, Vogl T, Loomba R, Plum-Mörschel L.
  Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
  ALIMENT PHARMACOL THER 2021 Sep 27. doi:10.1111/apt.16608. Online ahead of print.

• Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, Bandak B, Tehranchi R.
  Dasiglucagon: A next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia. Results of phase 3 randomized double-blind clinical trial.
  DIABETES CARE 44: 1-7, 2021. 

• Leohr J, Dellva MA, LaBell E, Coutant DE, Klein O, Plum-Moerschel L, Zijlstra E, Linnebjerg H.
  Pharmacokinetic and glucodynamic responses of ultra rapid lispro vs lispro across a clinically relevant range of subcutaneous doses in healthy subjects.
  Clin Ther 42: 1762-1777, 2020

• Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial. Br J Clin Pharmacol 2020 Oct 30. doi: 10.1111/bcp.14632. Online ahead of print

• Andersen G, Plum-Mörschel L, Hockings PD, Morsing A, Palle MS, Svolgaard O, Flint A.
  Clinical characteristics of a non-alcoholic fatty liver disease population across the fibrosis spectrum measured by magnetic resonance elastography: Analysis of screening data.
  Adv Ther 2020 Oct 1. doi: 10.1007/s12325-020-01503-x. Online ahead of print

• Linnebjerg H, Zhang Q, LaBell E, Dellva MA, Coutant DE, Hövelmann U, Plum-Mörschel L, Herbrand T, Leohr J.
  Pharmacokinetics and glucodynamics of ultra rapid lispro (URLi) versus Humalog (lispro) in younger adults and elderly patients with type 1 diabetes mellitus: A randomised controlled trial.
  CLIN PHARMACOKINET 2020 May 29. doi: 10.1007/s40262-020-0093-0. Online ahead of print

• Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier BM, Plum-Mörschel L.
  Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: A randomised, open-label, crossover study.
  DIABETES THER 2020 Jun 8. doi: 10.1007/s13300-020-00845-7. Online ahead of print
• Parker VER, Robertson D, Wang T, Hornigold DC, Petrone M, Cooper AT, Posch MG, Heise T, Plum-Moerschel L, Heike S, Klaus B, Ambery PD, Meier JJ, Hirshberg B.
  Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist.
  J CLIN ENDOCRINOL METAB 2019 Oct 14. doi: 10.1210/clinem/dgz047. (Epub ahead of print)
• Halberg IB, Lyby K, Wassermann K, Heise T, Plum-Mörschel L, Zijlstra E.
  The effect of food intake on the pharmacokinetics of oral basal insulin: A randomised crossover trial in healthy male subjects.
  CLIN PHARMACOKINET 2019 May 16. doi: 10.1007/s40262-019-00772-2. (Epub ahead of print)
• Meiffren G, Herbrand T, Anastassiadis E, Klein O, DeVries JH, Heise T, Alluis B, Megret C, Gaudier M, Soula O, Plum-Mörschel L.
  Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).
  DIABETES OBES METAB 2019 Mar 3. doi: 10.1111/dom.13685. (Epub ahead of print)
• Halberg IB, Lyby K, Wassermann K, Heise T, Zijlstra E, Plum-Mörschel L.
  Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial.
  LANCET DIABETES ENDOCRINOL 2019 Jan 21. doi: 10.1016/S2213-8587(18)30372-3. (Epub ahead of print)
• Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L.
  MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
  Lancet 2018 Jun 30; 391: 2607-2618. 
• Forst T, Alghdban MK, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
  Sequential treatment escalation with dapagliflozin and saxagliptin improves beta cell function in type 2 diabetic patients on previous metformin treatment: An exploratory mechanistic study.
  HORM METAB RES 2018 May 4. doi: 10.1055/a-0591-9442. (Epub ahead of print)
• Zijlstra E, Coester HV, Heise T, Plum-Mörschel L, Rasmussen O, Rikte T, Pedersen LK, Qvist M, Sparre T.
  Injecting without pressing a button: An explanatory study of a shield-triggered injection mechanism.
  DIABETES OBES METAB 2017 Dec 27. doi: 10.1111/dom.13203. (Epub ahead of print)
• Harris C, Forst T, Heise T, Plum-Mörschel L, Watkins E, Zhang Q, Fan L, Garhyan P, Porksen N.
  Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomized trial: IMAGINE 8.
  DIABETES TECHNOL THER 19: 463-470, 2017
• Forst T, Plum-Mörschel L, Weber MM.
  Cardiovascular aspects of diabetes treatment: Finally a reason for cardiologists to be pleased.
  INTERNIST (Berl.) 2017 Jan 24. doi: 10.1007/s00108-017-0189-0. (Epub ahead of print). (German)
• Forst T, Falk A, Andersen G, Fischer A, Weber MM, Voswinkel S, Heise T, Kapitza C, Plum-Mörschel L.
  Effects on alpha- and beta-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study.
  DIABETES OBES METAB 19: 489-495, 2017
• Porksen N, Linnebjerg H, Garhyan P, Lam ECQ, Knadler MP, Jacober SJ, Hoevelmann U, Plum-Moerschel L, Watkins E, Gastaldelli A, Heise T.
  Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.
  DIABETES OBES METAB 19: 482-488, 2017
• Heise T, Zijlstra E, Nosek L, Heckermann S, Plum-Mörschel L, Forst T.
  The euglycaemic glucose clamp: What it can and cannot do - and how to do it.
  DIABETES OBES METAB 18: 972-982, 2016
• Forst TA, Plum-Mörschel L, Heise T.
  Pharmacological intervention in type 2 diabetes mellitus - A pathophysiologically reasoned approach?
  CURR DIABETES REV 2016 Jun 13. (Epub ahead of print)
• Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L.
  Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
  DIABETES OBES METAB 17: 188-197, 2015
• Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mörschel L.
  Effect of the sodium glucose co-transporter 2 inhibitor, canagliflozin, on plasma volume in patients with type 2 diabetes mellitus.
  DIABETES OBES METAB 2014, Jun 17. doi:10.1111/dom.12322 (Epub ahead of print)
• Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P.
  Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
  J CLIN ENDOCRINOL METAB 98: E867-871, 2013

浏览Profil的发表物列表以查看我们的其他发表物。

主要成就及工作经验